Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.

Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR.

J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21.

PMID:
28870559
2.

Oxytocin and Migraine Headache.

Tzabazis A, Kori S, Mechanic J, Miller J, Pascual C, Manering N, Carson D, Klukinov M, Spierings E, Jacobs D, Cuellar J, Frey WH 2nd, Hanson L, Angst M, Yeomans DC.

Headache. 2017 May;57 Suppl 2:64-75. doi: 10.1111/head.13082. Review.

PMID:
28485846
3.

Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.

Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, Hanson LR, Kozarsky KF, Orchard PJ, Frey WH 2nd, Low WC, McIvor RS.

Hum Gene Ther. 2017 Jul;28(7):576-587. doi: 10.1089/hum.2017.187. Epub 2017 Apr 20.

PMID:
28462595
4.

Food consumption and activity levels increase in rats following intranasal Hypocretin-1.

Dhuria SV, Fine JM, Bingham D, Svitak AL, Burns RB, Baillargeon AM, Panter SS, Kazi AN, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2016 Aug 3;627:155-9. doi: 10.1016/j.neulet.2016.05.053. Epub 2016 Jun 2.

PMID:
27264485
5.

Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning.

Krishnan JKS, Arun P, Appu AP, Vijayakumar N, Figueiredo TH, Braga MFM, Baskota S, Olsen CH, Farkas N, Dagata J, Frey WH 2nd, Moffett JR, Namboodiri AMA.

Neurotoxicology. 2016 Mar;53:64-73. doi: 10.1016/j.neuro.2015.12.020. Epub 2016 Jan 2.

6.

Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders.

Tzabazis A, Mechanic J, Miller J, Klukinov M, Pascual C, Manering N, Carson DS, Jacobs A, Qiao Y, Cuellar J, Frey WH 2nd, Jacobs D, Angst M, Yeomans DC.

Cephalalgia. 2016 Sep;36(10):943-50. doi: 10.1177/0333102415618615. Epub 2015 Nov 20.

PMID:
26590611
7.

Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.

Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13.

PMID:
25445365
8.

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR.

CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.

PMID:
25373630
9.

Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease.

Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati A, Buadze M, Novakovic A, Proksch B, Gleiter CH, Frey WH, Schwab M.

Cell Transplant. 2014;23 Suppl 1:S123-39. doi: 10.3727/096368914X684970. Epub 2014 Oct 9.

PMID:
25302802
10.

Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.

Fine JM, Forsberg AC, Renner DB, Faltesek KA, Mohan KG, Wong JC, Arneson LC, Crow JM, Frey WH 2nd, Hanson LR.

Brain Res. 2014 Jul 29;1574:96-104. doi: 10.1016/j.brainres.2014.05.048. Epub 2014 Jun 10.

PMID:
24928620
11.

Intranasal insulin to treat and protect against posttraumatic stress disorder.

Frey WH 2nd.

J Nerv Ment Dis. 2013 Jul;201(7):638-9. doi: 10.1097/NMD.0b013e318298302e. Review. No abstract available.

PMID:
23817163
12.

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.

Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C.

CNS Drugs. 2013 Jul;27(7):505-14. doi: 10.1007/s40263-013-0076-8. Review.

13.

Intranasal delivery of insulin via the olfactory nerve pathway.

Renner DB, Svitak AL, Gallus NJ, Ericson ME, Frey WH 2nd, Hanson LR.

J Pharm Pharmacol. 2012 Dec;64(12):1709-14. doi: 10.1111/j.2042-7158.2012.01555.x. Epub 2012 Jul 4.

PMID:
23146033
14.

Intranasal treatment of central nervous system dysfunction in humans.

Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schiöth HB, Benedict C.

Pharm Res. 2013 Oct;30(10):2475-84. doi: 10.1007/s11095-012-0915-1. Epub 2012 Nov 8. Review.

15.

Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.

Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd.

Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2.

PMID:
25786865
16.

Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.

Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR.

Exp Brain Res. 2012 Jun;219(3):381-90. doi: 10.1007/s00221-012-3101-0. Epub 2012 May 1.

PMID:
22547371
17.

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

Wolf DA, Hanson LR, Aronovich EL, Nan Z, Low WC, Frey WH 2nd, McIvor RS.

Mol Genet Metab. 2012 May;106(1):131-4. doi: 10.1016/j.ymgme.2012.02.006. Epub 2012 Feb 10.

PMID:
22420937
18.

Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

Renner DB, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2012 Apr 4;513(2):193-7. doi: 10.1016/j.neulet.2012.02.037. Epub 2012 Feb 22.

PMID:
22387067
19.

Intranasal delivery of growth differentiation factor 5 to the central nervous system.

Hanson LR, Fine JM, Hoekman JD, Nguyen TM, Burns RB, Martinez PM, Pohl J, Frey WH 2nd.

Drug Deliv. 2012 Apr;19(3):149-54. doi: 10.3109/10717544.2012.657720. Epub 2012 Feb 22.

PMID:
22353012
20.

Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states.

Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC.

Mol Pain. 2012 Jan 11;8:3. doi: 10.1186/1744-8069-8-3. Retraction in: Mol Pain. 2014;10:20.

Supplemental Content

Support Center